
Health care special purpose acquisition companies in 2020-2021 represented a temporary market inefficiency that enabled weaker companies to bypass traditional due diligence and ultimately led to failures.
Supplements and Featured Publications
almost 25 years ago
Review of Clinical trial Data Reaffirms Safety of Statin Therapyalmost 25 years ago
Protective Effects of HDL-C and Need to Raise Low Levels Exploredalmost 25 years ago
New Cholesterol Guidelines Emphasize Risk Assessment



